JPMORGAN CHASE & CO - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 209 filers reported holding BRIDGEBIO PHARMA INC in Q2 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.5%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$5,644,999
+45.1%
214,069
-5.3%
0.00%
Q2 2023$3,889,556
-30.3%
226,137
-32.8%
0.00%
-100.0%
Q1 2023$5,577,000
+138252.8%
336,368
-36.4%
0.00%0.0%
Q4 2022$4,031
-99.9%
529,125
+82.3%
0.00%
Q3 2022$2,885,000
-17.3%
290,284
-24.4%
0.00%
Q2 2022$3,487,000
-54.1%
384,080
-48.7%
0.00%
-100.0%
Q1 2022$7,593,000
-70.5%
748,106
-51.5%
0.00%
-66.7%
Q4 2021$25,732,000
-62.2%
1,542,703
+6.1%
0.00%
-62.5%
Q3 2021$68,159,000
-30.7%
1,454,188
-9.8%
0.01%
-33.3%
Q2 2021$98,326,000
+9.3%
1,612,955
+10.4%
0.01%0.0%
Q1 2021$89,970,000
-6.6%
1,460,549
+7.8%
0.01%
-14.3%
Q4 2020$96,313,000
+99.2%
1,354,419
+3.9%
0.01%
+75.0%
Q3 2020$48,353,000
+44.7%
1,303,308
+27.2%
0.01%
+33.3%
Q2 2020$33,408,000
+24.9%
1,024,474
+11.0%
0.01%0.0%
Q1 2020$26,757,000
+28.8%
922,656
+55.7%
0.01%
+50.0%
Q4 2019$20,773,000
+64.3%
592,652
+0.6%
0.00%
+33.3%
Q3 2019$12,644,000
-50.0%
588,897
-35.8%
0.00%
-40.0%
Q2 2019$25,274,000917,4230.01%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q2 2023
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$55,099,00039.31%
M28 Capital Management LP 466,200$4,233,0004.74%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$282,034,0003.75%
Octagon Capital Advisors LP 933,743$8,478,0002.26%
VIKING GLOBAL INVESTORS LP 26,620,991$241,719,0001.11%
HHLR ADVISORS, LTD. 5,362,014$48,687,0001.04%
Cormorant Asset Management, LP 1,469,179$13,340,0001.01%
Knott David M Jr 213,206$1,936,0000.81%
Fernwood Investment Management, LLC 183,900$1,670,0000.72%
HighVista Strategies LLC 105,942$962,0000.58%
View complete list of BRIDGEBIO PHARMA INC shareholders